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Incorporation of Candida albicans Cell Wall Surface Proteins into Lipid Vesicles: 
Physicochemical Characterization and In vitro Cytotoxicity 
Abstract 
Over the past two decades, Candida species have become the fourth most common 
cause of bloodstream infections with mortality rates higher than 50%. A significant 
improvement has been made in chemotherapy for candidiasis with the availability of new azole 
derivatives and inhibitors of glucan synthase. However, the mortality rate for invasive 
candidiasis has remained stable. These observations underline the urgent need for the 
development of novel approaches to fight fungal infections. Candida albicans cell wall has in its 
composition cell wall surface proteins (CWSPs), which are important targets for the host 
immune system. Therefore, the present study was developed in order to compare two distinct 
lipid systems, one constituted by phosphatidylethanolamine (PE) and another composed by 
DODAB:MO, regarding their ability to incorporate antigenic CWSPs for a future development of 
a safe and effective vaccine against C. albicans.  
After the successful incorporation of the CWSPs into lipid vesicles three characteristics 
were analyzed: average size of the lipid-CWSPs vesicles, their polydispersity index (PDI) and 
incorporation efficiency (IE). The PE-CWSPs vesicles presented average sizes between 268.9 
nm and 492.4 nm and PDI values around 0.6. The MO, a neutral lipid, was included in the PE 
vesicles and the average size increased to 625.3 nm with PDI values of 0.5. DODAB:MO-
CWSPs vesicles average size ranged between 250.9 nm to 732.5 nm and the PDI values were 
considerably lower, around 0.3 to 0.5. After optimization of the delipidation method IE was 
determined and PE-CWSPs presented values ranging from 16.5% to 42.3%, whether PE:MO-
CWSPs vesicles presented lower values, around 25%. The DODAB:MO-CWSPs vesicles 
presented higher IE values, between 44.4% and 50,5%. Three formulations, PE (0.6mM)-
CWSPs, DODAB:MO (0.1mM)-CWSPs and DODAB:MO (0.3mM)-CWSPs were chosen, from a 
total of eight, according to its size, PDI value and incorporation efficiency, to be tested for in 
vitro cytotoxicity and no significant cytotoxicity was observed. 
With the information collected in this work both systems, PE-CWSPs and DODAB:MO-
CWSPs, were considered to be suitable for the development of a vaccine against C. albicans 
infections. 
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Incorporação de Proteínas da Superfície da Parede Celular de Candida albicans 
em Vesículas Lipídicas: Caracterização Físico-química e Avaliação da 
Citotoxicidade in vitro 
Resumo 
Ao longo das últimas décadas, as espécies do género Candida tornaram-se a quarta 
causa mais frequente de infeções sistémicas com taxas de mortalidade superiores a 50%. A 
quimioterapia contra candidíase tem melhorado significativamente com a disponibilização de 
novos derivados azólicos e inibidores da sintase dos glucanos. Contudo, a taxa de mortalidade 
de candidíase invasiva tem-se mantido estável. Estes estudos apontam para a necessidade 
urgente de desenvolver novas estratégias contra as infeções fúngicas. A parede celular de C. 
albicans contem proteínas à sua superfície (CWSPs), que são alvos importantes para o sistema 
imune. Desta forma, este estudo foi desenvolvido no sentido de comparar dois sistemas 
lipídicos distintos, um constituído por fosfatidiletanolamina (PE) e outro composto por 
DODAB:MO, no que respeita à capacidade para incorporar as CWSPs, para o futuro 
desenvolvimento de uma vacina segura e eficiente contra C. albicans.  
Após incorporação das CWSPs nas vesículas lipídicas foram analisadas três 
características: o tamanho médio das vesículas lipídicas, o seu índice de polidispersividade 
(PDI) e a sua eficiência de incorporação (IE). As vesículas PE-CWSPs apresentaram tamanhos 
médios entre 268,9 nm e 492,4 nm e valores de PDI entre 0,6. O lípido neutro MO foi incluído 
nas vesículas de PE e o tamanho destas aumentou para 625,3 nm com valores de PDI à volta 
de 0,5. As vesículas de DODAB:MO-CWSPs apresentaram tamanhos entre 250,9 nm e 732,5 
nm e valores de PDI consideravelmente mais baixos, entre 0,3 e 0,5. Depois da otimização do 
método de remoção dos interferentes lipídicos foi determinada a IE e as vesículas de PE-
CWSPs apresentaram valores entre 16,5% e 42,3% enquanto que as vesículas de PE:MO-
CWSPs apresentaram valores mais baixos, 25%. As vesículas de DODAB:MO-CWSPs 
apresentaram valores de IE mais elevados, entre 44% e 50,5%. De um total de oito 
formulações foram escolhidas três de acordo com o seu tamanho, polidispersividade e 
eficiência de incorporação, PE (0,6)mM-CWSPs, DODAB:MO (0,1mM)-CWSPs e DODAB:MO 
(0,3mM)-CWSPs. A citotoxicidade in vitro das formulações selecionadas foi determinada não 
tendo sido observados valores significativos de citotoxicidade. 
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Com a informação obtida neste trabalho, ambos os sistemas PE-CWSPs e DODAB:MO-
CWSPs foram considerados apropriados para o desenvolvimento de uma vacina contra as 
infeções provocadas por C. albicans. 
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Chapter 1 - General Introduction 
 
1.1 Fungal Infections 
 
Over the last two decades, invasive fungal infections have assumed a great importance, 
essentially due to the increasing population at risk. This population includes people with 
human immunodeficiency virus (HIV) infection, recipients of solid organ or hematopoietic stem 
cell transplants (HSCT), patients with hematologic malignancies, burns or indwelling medical 
devices and low-birth weight infants. A retrospective study in the United States of America 
(USA) shows an increase of 207% of cases of sepsis caused by fungal infections: from 5231 
cases in 1979 to 16042 cases in 2000 (Martin et al., 2003). In a large pan-European Sepsis 
Ocurrence in Accutely Ill Patients study it was reported that fungal infection was observed in 
17% of all septic patients in European Intensive Care Units (ICUs) (Vincent et al., 2006). 
Medical progress has led to an expanding population of susceptible hosts with impaired 
immunological defenses and are at heightened risk for invasive fungal infections including, 
aspergillosis, cryptococcosis and candidiasis (Warnock, 2007). 
Aspergillus fumigatus (A. fumigatus) is a saprophytic fungus that is important in 
recycling environmental carbon and nitrogen (Latge, 1999). Its natural ecological niche is the 
soil, where it survives and grows in organic debris. In the last years, A. fumigatus has become 
the most prevalent airborne fungal pathogen, causing severe and usually fatal invasive 
infections in immunocompromised hosts in developed countries (Andriole, 1993; Beck-Sague 
and Jarvis, 1993; Bodey et al., 1993; Dixon et al., 1996; Groll et al., 1996; Denning, 1998; 
Latge, 1999). 
Cryptococcus neoformans (C. neoformans) was first reported in Italy by a mycologist 
who cultured the fungus from peach juice (Sanfelice, 1984), it is also the etiologic agent of 
cryptococcosis, one of the most serious fungal infection encountered worldwide. Although C. 
neoformans can cause lesion in almost every organ, the most common clinical manifestation, 
as well as the most common cause of death is meningoencephalitis, an infection in the brain. 
Despite the most advanced medical treatment, the fatality rate for cryptococcosis is close to 
25%. While cryptococcosis sporadically occurs in normal individuals without any underlying 
condition, this disease is frequently associated with patients with Acquired Immunodeficiency 
Syndrome (AIDS) (Kwon-Chung and Bennett, 2010). 
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1.2 Candida Infections and Candidemia  
 
A significant cause of infection entails several species of Candida. Macroscopically, 
colonies of Candida spp. are cream-colored to yellowish. All species produces blastoconidia 
and many of them are dimorphic growing as budding yeast cells, pseudohyphae or true hyphae 
(Eggimann et al., 2003). Figure 1 depicts macroscopic and microscopic features of Candida 
albicans (C. albicans) cells.  
 
 
Figure 1- Macroscopic and microscopic features of C. albicans cells. Colonies of C. albicans cells in different 
filament inducing media (A, B and C). Fluorescence micrograph of calcofluor white stained C. albicans cells (D 
and E). Electronic Micrograph of C. albicans cells (F).  
 
In healthy individuals, Candida species belong to the normal microbial flora of skin and 
mucosal surfaces namely oral cavity, gastrointestinal tract and the vagina (Mavor et al., 2005). 
As commensals, Candida species are harmless, but if the balance of the normal flora is 
disrupted or the immune defenses are compromised, these fungi can outgrow and cause 
symptoms of disease, and consequently, two main types of infections can be observed: 
mucocutaneous or invasive candidosis.  
There are several risk factors for Candida infections, such as prior colonization with 
Candida species; HIV infection; cancer chemotherapy; neutropenia; organ transplantation; 
indwelling catheters and devices; autoimmune diseases; burn; antimicrobial therapy; age, 
gender, abdominal surgery and perforation, polytrauma, heart disease, pulmonology, 
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radiotherapy, rheumatology and any therapy involving prolonged exposure to steroid drugs 
(Eggimann et al., 2003; Mavor et al., 2005; Sabino et al., 2010)  
In the USA, the National Nosocomial Infections Surveillance (NNIS) program showed that 
incidence of primary Candida bloodstream infections (BSI) has increased by as much as 487% 
over the decade of the 1980’s in large teaching hospitals (Vincent et al., 1998). The countries 
participating in the European Confederation of Medical Mycology (ECMM) survey reported 
candidemia rates (0.31 to 0.44 per 10 000 patients-days) lower than the rates reported in the 
USA (1,5 per 10 000 patients-days) (Tortorano et al., 2006). Invasive candidiasis accounted for 
17% of hospital-acquired infections reported during the “European Study on the Prevalence of 
Nosocomial Infections in Critically Ill Patients” and candidemia represented 10-20% of all 
candidiasis (Beck-Sague and Jarvis, 1993; Jarvis, 1995; Pfaller, 1996). This genus is now 
classified as fourth on the list of nosocomial agent of sepsis (Wisplinghoff et al., 2004) and is 
associated with high morbidity and mortality. In patients hospitalized in ICUs and hospital 
wards, and those undergoing transplantation, the mortality attributed to candidemia ranged 
from 5 to 71% (Falagas et al., 2006).  
 
1.3 Cell Wall and Cell Wall Surface Proteins (CWSPs) 
 
C. albicans is a dimorphic organism, capable of existing as yeast or in a filamentous 
hyphal state. Interest in the C. albicans cell wall and associated proteins derives from basic 
research into the dimorphic nature of the organism and the potential of using cell wall targets, 
in particular cell wall proteins, in drug development, since mammalian cells lack a cell wall 
(Ebanks et al., 2006). The cell surface has two important roles: to maintain the integrity of the 
cell and to interact with the environment. Regarding its composition (Figure 2A and B) the cell 
wall has a flexible, three-dimensional network of β-1,3-glucan to which β-1,6-glucan and chitin 
are attached. The cell wall surface proteins (CWSPs) covalently attached to these two structural 
fibrillar polysaccharides can be divided in two classes. The first and most abundant class is 
linked to β-1,6-glucan through a glycophosphatidylinositol (GPI) remnant. The second class of 
proteins named Pir (proteins with internal repeats) are linked directly to β-1,3-glucan. Another 
class of proteins lacks the covalent attachment to the polysaccharide matrix and they may be 
heterogeneously distributed at the surface or secreted into the external milieu. “Atypical” 
proteins, such as succinate dehydrogenase (Sdh2) and pyruvate kinase (Cdc19), that were 
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previously identified in the cytosol and in other organelles have also been identified as 
belonging to the cell wall, however they lack the characteristics that are present in the “true” 
cell wall proteins: predicted signal peptide, potential O- and N- glycosylation site, GPI signature 
and series of internal repeats (Castillo et al., 2008). Phospholipomannan is also present in the 
cell wall with α-1,2-mannose linkages (Chaffin, 2008). 
  
 
Figure 2- Structure of C. albicans cell wall. A. Electron Micrograph and B. Schematic representation of the cell 
wall of C. albicans (Gow et al., 2012). 
 
CWSPs are essential for the life of fungi and particularly in the dimorphic fungus C. 
albicans. They are important in several roles including: enzymatic, cell interaction, antigenicity, 
pathogenicity, wall structure and morphogenesis (Ruiz-Herrera et al., 2006). Several proteins 
show enzymatic activities that are important in the degradation of complex molecules used as 
nutrients, while others are involved in the cleavage of the protective superficial structures of 
host cells and tissues enabling invasion. Proteins such as adhesins and lectins are important to 
allow the attachment of C. albicans cells to different host surfaces. Additionally, other enzymes 
are involved in the assembly of β-1,3 and β-1,6-glucans, and chitin. Specific cell wall 
components act as antigens or immunomodulators, whose effects can alter the balance 
between the fungus and its host (Castillo et al., 2008). CWSPs are very immunogenic 
molecules and are overexpressed during pathogenesis in human disseminated candidiasis, 
which indicates that induced antibodies will recognize the yeast cells. They are very 
conservative and exposed on the surface of the yeast cell and present themselves as important 
targets for the host immune response (Xin et al., 2008). 
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1.4 Host Immune Response 
 
During the infection process the fungus has to face different infection stages such as 
entering the bloodstream, surviving in the blood and escaping from the bloodstream to deep-
seated organs. There are two main routes of entry of Candida cells into the circulatory system: 
(i) the natural route which entails penetration through epithelial cells from mucosal surfaces 
into deeper tissues and blood capillaries or vessels and (ii) iatrogenic routes that include the 
use of medical devices and the ones caused by damaged barriers (Mavor et al., 2005). 
Effective host immune response against fungal organisms requires the coordinated 
contribution of both innate and humoral immunity (Antachopoulos and Roilides, 2005). The 
innate immune system confers rapid recognition of microbial agents and gives non-specific, 
broad spectrum responses. Physical barriers (skin, mucous membranes) are the first line of 
defense conferred by innate immunity and have antimicrobial substances on their surface. The 
skin and mucous membrane have a commensal microflora of saprophytic microorganisms that 
obstruct colonization by pathogenic microorganism. These barriers secret a group of peptides 
also called chemotactic factors that include leukotrienes and chemokines which can also be 
produced by leukocytes, endothelial cells, fibroblasts and smooth muscle cells after stimulation 
by cytokines (Blanco and Garcia, 2008). These chemotactic factors are critical factors in the 
defense once they enhance the effective recruitment of leucocytes to the site of infection 
(Blanco and Garcia, 2008).  
When fungi overcome physical barriers they have to face cellular barriers. According to 
Heindenreich (Heindenreich, 2010) there are several types of effector cells that protect the 
body and provide immunity. Among them are neutrophils, natural killer cells (NK), dendritic 
cells (DCs) and macrophages that are essential for protection against fungal pathogens. Loss 
or defects on these cells in their fungal effector functions result in susceptibility of the host 
(Blanco and Garcia, 2008; Brown, 2011). Neutrophils are classically characterized by their 
ability to act as phagocytic cells, to release lytic enzymes from their granules and to produce 
reactive oxygen intermediates with antimicrobial potential (Mantovani et al., 2011). NK cells 
are effector lymphocytes of the innate immune system that control microbial infections by 
limiting their spread and subsequent tissue damage and are regulatory cells engaged in 
reciprocal interactions with DCs, macrophages, T cells and endothelial cells (Vivier et al., 
2008). DCs are professional antigen-presenting cells (APCs) and are efficient stimulators of B 
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and T lymphocytes (Banchereau and Steinman, 1998). Forman and Torres (Forman and 
Torres, 2001) define macrophages as phagocytic cells that produce and release reactive 
oxygen species (ROS) in response to phagocytosis or stimulation with various agents. 
Macrophages play different roles in immunity once they are highly efficient in clearing 
pathogens and dying cells, and also in antigen presentation to primed T-cells. Macrophages 
can also secrete cytokines that affect migration and activation of other immune cells and 
reactive metabolites (Heinsbroek and Gordon, 2007). To eliminate pathogens, macrophages 
like other cells from the immune system, need to be able to distinguish self from non-self in 
either a direct or indirect way (Gordon and Taylor, 2005). The direct innate recognition of fungi 
by phagocytes is achieved mostly through the sensing of cell wall constituents and sometimes 
of internal compounds by Pattern Recognition Receptors (PRRs).  
Since Medzhitov (Medzhitov and Janeway, 1997) proposed the concept of pattern 
recognition, several PRRs have been identified and they recognize the so called pathogen-
associated molecular patterns (PAMPs). Figure 3 represents the PRR sensing C. albicans at the 
membrane level and the proinflammatory responses. The first PRRs discovered to recognize C. 
albicans were the Toll-like Receptors (TLRs) with TLR2 recognizing phospholipomannan, while 
TLR4 recognize O-linked mannan (Cheng et al., 2012). The second major PRR family that 
recognizes Candida PAMPs is the C-type lectin receptors (CLRs). β-glucans are recognized by 
dectin-1 and the N-linked mannan is recognized by the macrophage mannose receptor. DC-
SIGN is another important receptor cells that recognizes Candida mannan on the dendritic 
cells. Galectin-3 is important for the recognition of C. albicans β-mannosides and mannose-
binding lectin (MBL) mediates Candida cells opsonization and uptake binding Candida cells to 
the receptor on the phagocyte (Netea and Marodi, 2010).  
 
Figure 3 – PRR sensing C. albicans at the membrane level (Netea and Marodi, 2010). 
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The indirect recognition of the microorganism can be by coating and opsonization of the 
pathogen, allowing the recognition through membrane-bound opsonic receptors (Brown, 
2011). In the case of C. albicans, MBL is an opsonin that binds mannans in the cell wall both 
in vivo and in vitro, leading to complement deposition via lectin pathway and subsequent 
phagocytosis (Lillegard et al., 2006). Following internalization, the phagosomes matures 
through several sequential steps involving fusion and fission events, mostly with components of 
the endossomal network, leading to the formation of the phagolysossome, where the pH drops 
and antimicrobial molecules kill and digest the fungus (Brown, 2011). In addition to being 
important for intracellular killing, phagocytosis deliver signals for subsequent regulatory and 
microbicidal functions of the phagocytes (Vazquez-Torres and Balish, 1997). The process of 
phagocytosis is represented in Figure 4. 
 
 
Figure 4– Schematic representation of phagocytosis (adapted from (Heinsbroek and Gordon, 2007). 
 
Macrophages need to be activated to mobilize those potent microbicidal mechanisms 
that eliminate the intracellular pathogen. According to Gordon and Taylor (Gordon and Taylor, 
2005) monocytes are recruited and differentiated into macrophages at the site of inflammatory 
lesion. Then they are activated, which is critical for stimulation of candidacidal activity. Of all 
cytokines that activate macrophages IFN-γ is considered an excellent stimulator of the capacity 
of macrophages to kill C. albicans. The enhanced killing of C. albicans coincides with the 
activation of multiple oxygen-dependent and independent mechanisms (Vazquez-Torres and 
Balish, 1997). ROS such as O2.-, H2O2 are generated both enzymatically by oxidoreductases and 
non-enzymatically as side products of reactions that use electron transfer. Reactive Nitrogen 
Species (RNS) are also produced by macrophages to enhance killing in which the main 
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example is Nitric Oxide (NO) which is enzymatically produced by nitric oxide synthases through 
the oxidation of L-arginine in the presence of oxygen and NADPH (Forman and Torres, 2001). 
Figure 5 summarizes the reactions involved in the generation of ROS and RNS: 
 
 
Figure 5 – Generation of ROS and RNS by macrophages (Forman and Torres, 2001). 
 
C. albicans cells have been shown to be susceptible to some oxygen-dependent killing 
mechanisms of mononuclear phagocytic cells: O2.- anion, hydrogen peroxide-halide system, and 
RNS (Vazquez-Torres and Balish, 1997). Phagocytic cells also have nonoxidative mechanisms 
that help in the destruction of the fungus, namely the production of anti-microbial peptides 
such as α-defensins that bind to specific sites on the fungal membrane, inducing nonlytic 
permeabilization and the release of intracellular component such as ATP (Vylkova et al., 2007). 
Hydrolases, lysozyme, collectin and lactoferrin also play an important role against pathogens. 
The antimicrobial activity of these proteins is related to lysis or opsonization of the pathogen 
(Jenssen and Hancock, 2009). According to Brown (Brown, 2011) the activation of these 
proteases by respiratory burst is a primary mechanism of microbial killing. Other antifungal 
mechanism is the limitation of nutrients. This is achieved by restraint of the ingested pathogen 
within the phagosomes and by active restriction of nutrients: limiting iron, sequestration of zinc 
among others. 
As an APC the macrophage is able to load degraded material from the endocytic 
pathway, particularly from phagocytosis, onto Major Histocompatibility Complex Class II (MHC 
II) molecules for antigen presentation to primed T cells leading to T-cell activation (Brown and 
Netea, 2007). The activated T-cells produce IFN-γ which activates macrophages, increasing 
their antigen presentation (Brown and Netea, 2007). Once the antigen is eliminated, central 
memory (TCM) and effector memory (TEM) T cells persist in the memory pool to provide systemic 
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immune surveillance in lymphoid organs and in peripheral non-lymphoid tissues to react 
promptly in case of re-attack.  
There is another barrier against fungi known as humoral barrier. It includes natural 
occurring antibodies and the complement system, the last refers to a group of proteins that 
interact in different pathways to assist immune cells in destroying foreign invaders 
(Heidenreich, 2010). According to Blanco and Garcia (Blanco and Garcia, 2008) humoral 
immunity can protect against fungal infections if certain types of protective antibodies are 
available in sufficient quantity. The main recognized functions of antibodies are antibody 
dependent cellular toxicity, prevention of adherence, antibody opsonization and toxin 
neutralization (Blanco and Garcia, 2008).  
In general the innate immune system includes all aspects of the host’s immune defense 
mechanism that are encoded in their mature functional forms by the germ-line genes of the 
host. In contrast to innate immunity, acquired immunity requires recognition of specific foreign 
molecules and develops memory T cells (Deepe, 1997). Fungal antigens are collected and 
processed by dendritic cells that transport them to draining lymph nodes where the antigens 
are presented to T helper and regulatory T cells. T helper cells give either Th1 (protective) 
cytokines such as TNF-α, IFN-γ, IL-1, IL-6 and IL-12 or Th2 (nonprotective) cytokines (IL-10, IL-
4 and IL-5). TNF-α is an important cytokine against fungi and stimulates the antifungal activity 
of neutrophils and macrophages and also polarizes T helper cells towards a Th1 response 
(Ben-Ami et al., 2008). More recently, Th17-type adaptive immunity was implicated in the 
control of fungal infections, particularly at the mucosa level, although this may be relevant only 
at specific mucosal sites and for specific pathogens (Brown, 2011).  
Knowing the crucial role of the host’s immune response in controlling invasive fungal 
infection the development of immunomodulation strategies is important to fight fungal 
infections (Ben-Ami et al., 2008). 
 
1.5 Antifungal Strategies 
 
The advancements of medicine, surgery and transplantology in the last thirty years 
have caused dramatic increase in the number of immunocompromised individuals who are 
more susceptible to fungal infections. On the other hand, the pharmacologic treatment of 
invasive fungal infections has been mainly performed with only four antifungal drugs 
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(amphotericin B, flucytosine, fluconazole and caspofungin) which highlight the fact that the 
available antifungal agents are still very limited compared to antibiotics. The new azole 
derivatives and inhibitors of glucan synthase promised to improve the efficacy of antifungal 
prophylaxis and treatment in patients at risk and in refractory or resistant cases, but despite 
the introduction of these new agents the mortality rate for invasive candidiasis remained 
stable from 1997 to 2007 (Pfaller et al., 2010). 
Generally, the antifungal procedures are based on the differences between fungal and 
mammalian cells. The classes available include (Dan and Levitz, 2006): 
 Amphotericin B (a polyene) which binds to ergosterol in the membrane, forming 
transmembrane channels through which intracellular molecules leak; 
 Azoles, such as fluconazole, itraconazole, voriconazole, posaconazole, and allylamines 
(terbinafine), which target ergosterol enzymatic pathway, inhibiting its synthesis; 
 Echinocandins, such as caspofungin and micafungin, which target and inhibits 
synthesis of the cell wall polysaccharide, β-1,3-glucan; 
 Flucytosine that is an anti-metabolite of DNA and RNA synthesis.  
Figure 6 summarizes the mechanisms of action of these antifungal drugs.  
 
 
Figure 6– Mechanisms of action of antifungal drugs. (1) polyenes (amphotericin B) that disrupt membrane 
integrity; (2) triazoles that inhibit the key enzyme of ergosterol synthetic pathway; (3) echinochandins that inhibit 
the enzyme 1,3 β-D.glucan synthase; (4) 5-Flucytosine  (5-FC) that is converted in 5-fluorouracil (5-FU) which is 
converted in metabolites that inhibit fungal DNA and RNA synthesis (Ben-Ami et al., 2008). 
 
However, according to the same author, success rates for many mycoses remain 
unacceptably low and drug therapy is often limited by toxicity, resistance and cost. Therefore, 
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this urges the need for the development of prophylactic and/or therapeutic vaccines effective 
against fungal infections (Torosantucci et al., 2005).  
Vaccination of high-risk groups is a particularly promising strategy to prevent invasive 
fungal infections because easily identifiable risk factors are clearly defined for these infections. 
These risk factors precede infections which afford a window of opportunity to vaccinate acutely 
at risk patients before the onset of the infection. One major concern about vaccinating such 
patients against invasive fungal infections has been the assumption that the immune system of 
patients at risk for these infections is too weak to respond to vaccination. However, only 10-
20% of patients who develop candidemia are seriously immunocompromised (Spellberg, 
2011). 
Several studies have identified Candida molecules as antigen suitable for vaccine 
strategies such as ALS (agglutinin like sequence) proteins, or cell wall proteins such as Hyrp, 
or even other cell wall components such as β-glucan, using other proteins carriers or adjuvants 
to enhance activation (Spellberg et al., 2006; Luo et al., 2010; Pietrella et al., 2010). 
According to Henrisken-Lacey and colleagues (Henriksen-Lacey et al., 2011) vaccines 
constituting highly purified peptide or protein antigens are at the vanguard of vaccine research 
due to some important characteristics such as safety, relatively easy scale-up production and 
low production cost as compared with the live-attenuated or killed vaccines. However, they also 
possess some drawbacks that need to be taken into account: poor immunogenicity owing to 
the lack of PAMPs and rapid degradation which reduces the dose-effectiveness of such 
vaccines. These disadvantages raise the need for the use of new delivery systems. In the last 
ten years a significant amount of research has focused on using liposomes not only as antigen 
delivery system but also as a tool to increase immunogenicity of peptide and protein antigens 
(Henriksen-Lacey et al., 2011). 
 
1.6 Vesicular Systems 
 
Vesicles are nano/microparticulate colloidal carriers which form spontaneously when 
certain lipids are hydrated in aqueous media (Elizondo et al., 2011).  
Almost 75 years ago Paul Elrich came up with the concept of “magic bullet” picturing a 
drug delivery mechanism that would target drugs to diseased cells and A.D. Bangham in the 
early 60´s established that a broad diversity of molecules could be encapsulated within 
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liposomes or inserted in their membranes. These notions were crucial for the development of 
vesicles as drug delivery systems. Examples of drugs that have been improved with the use of 
liposomes include AmBisome® that enhance the solubility and targeting of Amphotericin B, 
and Caelyx® or Myocet® that promote tumor targeting and minimize nonspecific drug toxicity 
of anticancer agents such as doxorubicin.  
Liposomes have properties that make them valid for vaccine delivery: (i) entrap and 
protect antigen from degradation; (ii) deliver poor soluble antigens; (iii) present different 
pharmacokinetics depending on the vesicle composition, charge and size; (iv) reduce toxicity by 
shielding the antigen and (v) be avidly taken up by APCs (Henriksen-Lacey et al., 2011).  
Among the different types of vesicular systems used for drug delivery the liposomes 
(constituted mainly by phospholipids) and vesicles containing nonionic (niosomes), cationic 
(cationic vesicles) or both cationic and anionic surfactants (catanionic vesicles) are the most 
investigated for this purpose (Elizondo et al., 2011). 
The good performance of vesicular systems is related to their structure at 
supramolecular, microscopic and nanoscopic level (Elizondo et al., 2011). This highlights the 
importance of the lipid vesicular systems characterization mainly regarding the lamellarity, size 
and size distribution, zeta potential and incorporation efficiency. 
According to Elizondo and coworkers (Elizondo et al., 2011) regarding size and 
lamellarity different types of vesicles can be achieved from the self-assembly of a certain 
amphiphilic molecule: small unilamellar vesicles (SUVs, d≤200 nm), large unilamellar vesicles 
(LUVs, d≥200 nm), multilamellar vesicles (MLVs) and multivesicular vesicles (MVVs) all of them 
represented in Figure 7.  
 
 
Figure 7 – Types of vesicles according to size and lamellarity: A. Small Unilamellar Vesicles (SUVs); B. Large 
Unilamellar Vesicles (LUVs); C. Multilamellar vesicles (MLVs); D. Multivesicular Vesicles (MVVs) (adapted from 
(Elizondo et al., 2011)).  
 
 
   A                                    B                                         C                                       D  
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Several techniques are available for evaluating liposomes size and size distribution 
(Edwards and Baeumner, 2006): dynamic light scattering (DLS) (Ruf et al., 1989; Ruozi et al., 
2005), microscopy techniques such as cryoelectron microscopy (McCracken and Sammons, 
1987; Jass et al., 2003; Frederik and Hubert, 2005), size exclusion chromatography 
(Grabielle-Madelmont et al., 2003), field flow fractionation (Moon and Giddings, 1993; Korgel 
et al., 1998; Arifin and Palmer, 2003) and analytical centrifugation (McCracken and Sammons, 
1987). From all, the DLS technique is non-invasive, easier and faster than the other methods 
(Elizondo et al., 2011). DLS measures the time-dependent fluctuations of light scattered from 
particles experiencing Brownian motion, which results from collisions between suspended 
particles and solvent molecules. 
In order to achieve an optimal performance of the lipid vesicles it is also important to 
know the size distribution of the suspension and infer about the homogeneity of the lipid 
suspension. Figure 8 shows a schematic illustration of the response to an external stimulus 
presented by two hypothetical vesicular systems with homogenous and heterogeneous 
characteristics in terms of size and lamellarity. With the homogenous system the encapsulated 
drug would be released at the same time resulting in a sharp response while the 
heterogeneous system the drug release would take a longer period of time and the drug would 
not be liberated when required (Elizondo et al., 2011).  
 
 
Figure 8- Schematic illustration of the response to an external stimulus presented by a heterogenous vesicular 
system A. and a homogenous vesicular systems B. (Elizondo et al., 2011). 
 
As well as size and size distribution, surface properties of vesicles are also important for 
the characterization of the vesicular systems. Zeta potential is a physical property that is 
exhibited by any particle in suspension and is explained as the overall charge that a particle 
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acquires in a particular medium. This measurement can be achieved by Laser Doppler 
Velocimetry technique, where a voltage is applied across a pair of electrodes at either end of a 
cell containing the particle dispersion (Clogston and Patri, 2011). Charged particles are 
attracted to the oppositely charged electrode and their velocity is measured in unit field 
strength as their electrophoretic mobility. It is described that colloids with low zeta potential are 
not stable and tend to coagulate or flocculate while colloids with high absolute zeta potentials 
(above 30mV) values are electrically stable (Clogston and Patri, 2011). So, Zeta Potential also 
gives important information about the stability of the vesicular systems. 
Apart from the structural characterization the ability of a vesicular formulation to 
encapsulate the desired molecule is also very important. This ability of encapsulation can be 
referred as incorporation efficiency (IE) once it is more indicated for cases in which there is 
uncertainty whether the drug is encapsulated or integrated in the vesicular membrane.  
The measurement of IE requires methods for the rapid physical separation of particles 
from their surrounding dispersion medium to enable real-time determination of the proportion 
of free molecules (Wallace et al., 2012). Most methods for measurement of encapsulation 
separate the particles from the medium in which they are dispersed and there are numerous 
based on dialysis, filtration and centrifugation (Cui et al., 2006; Ricci et al., 2006; Zheng et al., 
2006; Wang et al., 2009). After the separation it is important to quantify the encapsulated 
material. The methods used will depend on the type of molecule that is encapsulated.  
Phospholipids are the most commonly used lipids as delivery systems, in particular the 
neutral phosphatidylcholine and the negatively charged phosphatidic acid, 
phosphatidylglycerol, phosphatidylserine and phosphatidylethanolamine, each of which has a 
different combination of fatty acid chains in the hydrophobic regions of the molecule. Besides 
the charge, the nature of the fatty acid residues in each lipid molecule, particularly the number 
of double bonds in the chain is responsible for bilayer properties such as phase behavior and 
elasticity are also important characteristics in the development of delivery systems (Jesorka 
and Orwar, 2008).  
Augustyniak and co-workers (Augustyniak et al., 2010) aimed to determine the 
effectiveness of phosphatidylcholine liposomes in potentiating a systemic immune response to 
Moraxella catarrhalis outer membrane proteins. For this study they used soya bean L-α-
phosphatidylcholine to form liposomes and were able to show that the proteoliposomes 
prepared had immunogenic properties.  
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Geros and coworkers (Geros et al., 1996) showed a successful reconstitution of a 
lactate-proton symport in a hybrid vesicle system obtained by fusing yeast plasma membrane 
with liposomes prepared from Escherichia coli (E. coli) phosphatidylethanolamine containing 
cytochrome c oxidase, a transmembrane protein. More, these vesicles were able to generate 
an electrical potential. 
In the last years cationic lipids become commonly used as a transfection reagents for 
DNA, RNA or proteins and as a coadjuvant of antigens for vaccination trials (Lonez et al., 
2012). Cationic lipids are made of two domains: a positively charged headgroup and a 
hydrophobic domain. The assembly into liposomes can be dependent on the addition of neutral 
lipids, also called helper lipids, such as cholesterol. The surface of these liposomes is positively 
charged which enhance the adsorption to the negatively charged cell surface (Lonez et al., 
2012). Several studies have revealed that cationic vesicles induce stronger immune responses 
against co-administrated antigen when compared to neutral and anionic liposomes 
(Christensen et al., 2012). Due to the fact that cationic liposomes are positively charged and 
cell membranes are negative Lincopan and coworkers (Lincopan et al., 2009) believe that 
particles for vaccines should be positive and available in a range of sizes. Until now cationic 
particles of aluminum compounds, identified as having immunostimulatory properties, remain 
the only type of adjuvant licensed world-wide (Caputo et al., 2008). 
Neves Silva and coworkers (Neves Silva et al., 2008) developed a 
Dioctadecyldimethylammonium Bromide (DODAB): Monoleein, 1-monooleoyol-rac-glycerol (MO) 
based lipoplexe. Lipoplexes are commonly used as non-viral delivery systems for transfection 
purposes. The long-chain cationic surfactant DODAB is a synthetic lipid, which in the presence 
of excess water and above the phase transition temperature tends to form LUVs. MO is an 
amphiphilic neutral lipid and it was reported (Neves Silva et al., 2008; Oliveira et al., 2010) 
that the inclusion of MO in the cationic liposomes formulations promotes the existence of 
inverted structures, different from the usual hexagonal morphology, due to MO tendency to 
form inverted cubic phases. The authors presented some important characteristics about this 
lipid system such as the non-cytotoxicity of the DODAB:MO lipoplexes and its transfection 
efficiency comparable to lipofectamine (Neves Silva et al., 2008). 
The understanding of the physicochemical characteristics of the lipid vesicles allied with the 
incorporation efficiency are important parameters in the study of lipid systems to guide in the 
selection for the most suitable system in the development of a vaccine against C. albicans.
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Chapter 2 - Objectives and Strategy 
 
This work is included in a laboratory project performed by our working group that 
proposes the development and characterization of a vesicular system composed by 
DODAB/MO as potential peptide antigen delivery systems for immunization trials.  
The main objective of this study is to compare two lipid systems: one that is based on 
the phospholipid PE that has been successfully used in the incorporation of a lactate-proton 
symport in our Department with liposomes prepared from E.coli and another, the named 
DODAB:MO system that has been effectively used for genetic transfection, regarding their 
ability to encapsulate the antigenic C. albicans CWSPs in the development of a safe and 
effective vaccine against this pathogenic fungus.  
Thus, this work enrolls several purposes: 
1) Incorporate CWSPs in PE and DODAB:MO based lipid vesicles and characterize 
them according to vesicle size and size distribution; 
2) Assess the incorporation efficiency of the formulation and select the most suitable 
formulations; 
3) Evaluate the in vitro cytotoxicity of the selected formulations in the macrophage like 
J774 cell line. 
The work presented was developed in the Centre of Molecular and Environmental 
Biology (CBMA) of Minho University. 
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Chapter 3 - Materials and Methods 
 
3.1 Extraction of Cell Wall Surface Proteins 
 
Proteins from the cell wall (CWSPs) of C. albicans (strain SC5314) were extracted after 
the optimization of the protocol described by Insenser and co-workers (Insenser et al., 2010). 
Briefly, cells were grown in YPD medium (Yeast Extract 1%, Glucose 2%, Bactopeptone 1%) at 
26 ºC with agitation of 180 rpm until an OD of 5-6. Then, cells were harvested through 
centrifugation (8000 rpm, 5 minutes) and the pellet washed two times with 50 mM Tris-HCl, 
pH 7.5. After the washing step, dithiothreitol (DTT) was added to the buffer and incubated with 
the cell suspension for 2 hours at 4 ºC with agitation. Then, the cell suspension was 
centrifuged (8000 rpm, 5 minutes), the supernatants collected and filtrated to remove the 
remnant cells. The supernatants were then centrifuged (25 minutes, 4000 g) in Amicon® 
filters with a membrane cut-off of 3kDa, for protein concentration. Protein was quantified using 
the Bradford Method and the concentration was adjusted to 50 μg/ml with Phosphate Buffered 
Saline (PBS) and stored in aliquots at -80 ºC. 
 
3.2 Evaluation of membrane integrity after CWSPs extraction 
 
In order to extract only the CWSPs, a method based on DTT was used, as explained in 
3.1. To ensure that this method of extraction did not disrupt the cell membrane and that 
cytoplasmic proteins were not extracted, membrane integrity, before and after cells incubation 
with DTT, was evaluated through flow cytometry. For this analysis, cells were incubated with a 
fluorescence probe Sytox Green, that intercalates in DNA when plasma membrane is 
compromised, according to a protocol described by Insenser and co-workers (Insenser et al., 
2010). Briefly, cells were incubated with Sytox Green (50 μM) after cell treatment with DTT for 
5 minutes in the dark. An aliquot of the cell suspension before DTT treatment was also 
fluorescently stained for control. Cells boiled for 5 minutes were used as control of dead cells 
(plasma membrane totally compromised) and cells with no staining were used to determine 
autofluorescence (AF). The stained cells were analyzed with a Beckman Coulter Epics Xl flow 
cytometer. 
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3.3 Analysis of CWSPs Electrophoretic Pattern 
 
In order to analyze the electrophoretic pattern of the CWSPs extracted using the 
reducing agent DTT, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed. For that, Resolution (12%) and Concentration gels (4%) were prepared as 
described in Table 1. CWSPs were prepared in denaturing conditions in which the sample 
buffer was constituted by Tris-HCl (63 mM, pH 6,8), Glycerol (10%), SDS (2%), Bromophenol 
Blue (0.0025%); DTT (7.5 M). Samples were then heated at 100 ºC for 10 minutes, incubated 
on ice for 10 minutes and centrifuged (13400 g) for 2 minutes. The running buffer was 
prepared with 0.025 M Tris, 0.192 M glycin and 0.1% SDS. After the sample treatment, a 
volume of 15 μl of each sample was loaded on the gel and the electrophoresis was performed 
during 3 hours with a voltage of 60 V.  
 
Table 1: Volumes used for Resolution and Concentration Gels for SDS-Page Electrophoresis of the CWSPs 
 Resolution Gel (12%) (μl) Concentration Gel (4%)( μl) 
Polyacrilamide 8000 650 
Tris-HCl (1.5M pH 8.8) 5000 0 
Tris-HCl (0,5M pH 6,8) 0 1250 
SDS  10% 2000 50 
H2O MiliQ 4890 3000 
TEMED 10 5 
Ammonium persulfate (APS) 10% 100 25 
 
After the electrophoresis, proteins were silver stained, according to Cupo and co-workers 
(Cupo et al., 1990). Briefly, gels were washed in deionized water for 5 minutes and soaked in 
fixative solution I (40% methanol, 10% acetic acid and 0.076% formalin in water) for 1 hour. 
Gels were then placed on fixative solution II (10% Ethanol and 5% acetic acid in water) for 2 
hours or overnight. After the incubation time gels were washed in water, soaked in oxidizer 
solution (3.4 mM potassium dichromate and 3.2 mM nitric acid in water) for 30 minutes and 
washed again 3 times with water. Then gels were incubated in 12 mM silver nitrate for 30 
minutes. After that, gels were washed 2 times in deionized water and developed by soaking 
them in developer solution (250 mM sodium carbonate and 0.05% of 37% w/v formalin water). 
When the bands appeared the development was stopped by placing the gels in stopping 
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solution (5% acetic acid in water). Gels were photographed and preserved in a solution of 30% 
ethanol, 10% acetic acid and 10% glycerol.  
 
3.4 Lipid Vesicles Preparation 
 
The step following the CWSPs extraction was the preparation of the lipid-CWSPs vesicles, 
using two lipid systems: phosphatidylethanolamine (PE) and DODAB:MO. In these two systems 
the lipid vesicles were prepared and the CWSPs incorporated, as explained below. 
PE-CWSPs vesicles were prepared by two different methods: film hydration (HFL) and 
freeze-thaw-sonicate (FTS). PE-CWSPs liposomes were prepared through FTS according to 
Geros and co-workers (Geros et al., 1996) with some alterations. Briefly, commercial E. coli PE 
(Sigma Aldrich P8068) was kept in aliquots of 10mg/ml in chloroform solution at – 80 °C. To 
prepare the liposomes, chloroform was removed under a stream of dry N2. Lipids were then 
ressuspended in 50 mM-potassium phosphate (pH 6.2) and mixed with 1 ml of CWSPs (50 
μg/ml). Then, the PE-CWSPs suspension was frozen in liquid nitrogen, thawed at room 
temperature and sonicated for 15 seconds and this procedure of FTS was repeated 5 times.  
PE-CWSPs liposomes were also prepared through film hydration method. Defined 
volumes from the stock solution of PE were mixed with 1 ml of CWSPs (50 μg/ml) and placed 
in a rotary evaporator fitted with an aspirator and a bath at 150 rpm until the solvent was fully 
evaporated and the film formed. The transition temperature of the PE is 0 ºC and DODAB is 50 
ºC so in order to standardize the bath conditions (in PE and in DODAB:MO) the bath was 
adjusted to approximately 55 ºC. 
After solvent evaporation, the lipid film was solubilized by adding the appropriate volume 
of Potassium Phosphate Buffer (50 mM, pH 6.2) and rotated until the lipid film was totally 
dispersed in the aqueous phase. 
In order to confirm the formation of PE-CWSPs closed vesicles FM1-43 probe was 
incubated with the formulations. FM1-43, a membrane probe, was incorporated in the PE-
CWSPs formulations after the formation of the lipid-CWSPs vesicles and allowed to incubate for 
15 minutes. After the incubation time the fluorescence was analyzed by flow cytometry. 
DODAB:MO-CWSPs formulations were prepared by film hydration method using a similar 
procedure of PE-CWSPs. Defined volumes from the stock solutions of DODAB and MO in 
ethanol were mixed. The mixture of DODAB, MO and 1 ml of CWSPs (50 μg/ml) was placed in 
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a rotary evaporator fitted with an aspirator and a bath with a temperature of 55 ºC at 150 rpm 
until the solvent was fully evaporated and the film formed. After solvent evaporation, the lipid 
film was solubilized with the addition of appropriate volume of PBS and rotated until the lipid 
film was totally dispersed in the aqueous phase.  
 
3.5 Lipid Vesicles Physicochemical Characterization  
 
With the purpose to characterize the lipid-CWSPs vesicles two physicochemical 
parameters were assessed: size (z-average diameter) and Polydispersity Index (PDI). The size 
and PDI of all liposome formulations and preparations were determined by DLS using ZetaSizer 
(Malvern). 
 
3.6 Incorporation Efficiency Determination 
 
The incorporation efficiency is an important characteristic in the development of delivery 
systems. Thus, after lipid vesicles preparation with the CWSPs, ultracentrifugation was 
performed (100000 g, 15 minutes) in order to separate the supernatant with the non-
incorporated CWSPs from the pellet with the lipid vesicles and the incorporated CWSPs.  
Following this separation step it was important to quantify the amount of incorporated 
protein. However, lipids strongly affect protein quantification and to overcome this problem 
several procedures, that remove the lipid interference, were performed: 
1. The N-Butanol Extraction, based on Zhu and co-workers (Zhu et al., 2011) with some 
alterations. Briefly, each Lipid-CWSPs formulation was mixed with 2-butanol and vortexed for 
10 seconds at maximum speed. Then, the mixture was allowed to incubate for 40 minutes at 
55 ºC. Afterwards, it was centrifuged at 13000 g for 1 minute and the aqueous phase 
transferred to new tubes and, this centrifugation was repeated. After that, a volume 100 μl of 
the aqueous phase was kept for protein quantification.  
2. The methanol and chloroform delipidation method performed according to Wessel 
and Flugge (Wessel and Flugge, 1984). Firstly, 400 μl of methanol were added to 100 μl of the 
sample that was vortexed and centrifuged (10 seconds, 9000 g). Then, 100 μl or 200 μl of 
chloroform were added to the samples with lower and higher lipid content, respectively, 
vortexed and centrifuged again (10 seconds, 9000 g). Following, 300 μl of water were added, 
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and the suspension vortexed and centrifuged (1 minute, 9000 g). Here, the upper phase was 
removed and discarded. Then, 300 μl of methanol were added, vortexed and centrifuged (2 
minutes, 9000 g). After this centrifugation the supernatant was removed and the protein pellet 
dried under a stream of air, for subsequent protein quantification.  
3. The protocol based on sample treatment with Triton X-100 was performed according 
to Xu and co-workers (Xu et al., 2012). Briefly, 100 μl of 6% (v/v) Triton X-100 were mixed with 
500 μl of the sample and the sample maintained at 65 ºC for 5 minutes to disrupt all vesicles. 
After this treatment the concentration of protein was quantified.  
4. The Trichloroacetic Acid (TCA) protein precipitation method. This method was 
performed according to the Tech Tip #8 of Thermo Scientific (Pierce ®). Firstly, 450 μl of 
water were added to 50 μl of each sample. Then, 100 μl of a solution of 0.15 % (w/v) sodium 
deoxycholate were added followed by the addition of 100 μl of 72% (w/v) TCA. The mixture 
was allowed to incubate for 10 minutes at room temperature. After the incubation time, 
samples were vortexed and centrifuged (10 minutes, maximum speed). The supernatant was 
removed and the pellet solubilized in a solution of 5% Sodium dodecyl sulfate (SDS) (w/v) in 
0.1 N sodium hydroxide (NaOH). Then, protein concentration was measured. 
After delipidation optimization CWSPs were quantified in the supernatant and in the 
pellet through two methods: the Bradford method and the BCA method. The Bradford assay is 
based on the binding of the Coomassie Blue dye at acidic pH to arginine, histidine, 
phenylalanine, tryptophan and tyrosine residues and after binding to proteins there is a shift 
from 465 nm to 595 nm due to stabilization of the anionic form of the dye. For quantification 
20 μl of each sample were plated in triplicate in a 96-well plate. A volume of 250 μl of 
Bradford solution (100 mg of Commassie Blue G-250; 50 ml of 95% ethanol; 100 ml of 85% 
phosphoric acid and 850 ml of ultrapure water) was added and incubated for 10 minutes. After 
the incubation time the absorbance was read at 595 nm. The BCA method is based on the 
conversion of Cu2+ to Cu+ under alkaline conditions and the BCA reacts with Cu+ resulting in the 
development of an intense purple color with an absorbance maximum at 562 nm. For this 
assay the Pierce ® BCA Protein Assay Kit was used and quantification was performed 
according to the kit instructions.  
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3.7 Macrophage culture  
 
The murine macrophage-like cell line J774A. 1 (American Type Culture Center number 
TIB 67 (Ralph and Nakoinz, 1975)), was routinely cultured in Dulbecco’s modified Eagle's 
medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FBS), 1% 
glutamine, 1% sodium pyruvate, and 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer in 5% CO2 at 37 °C. Sub-cultures were performed into new cell-culture flasks 
every 2 days. After confluent growth, macrophage cells were recovered and washed. Viable 
cells were determined by Trypan blue exclusion counting with the hemocytometer, and re-
suspended in DMEM to a final concentration of 4x105 cells/ ml.  
 
3.8 Determination of in vitro cytotoxicity of lipid vesicles – MTT Assay 
 
In order to assess the in vitro cytotoxicity of the lipid-CWSPs formulations in the J774 cell 
line, the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Mosmann, 
1983) was used. This is a rapid colorimetric assay that measures metabolic active cells once it 
is based on the reduction, by cellular reductases, of MTT in formazan (Mosmann, 1983). 
Firstly, 1 ml of the J774 cell suspensions (5x105 cells/ ml) was placed in each well of 24 
wells plates and macrophages allowed to incubate overnight for adherence. Then, defined 
volumes of the Lipid-CWSPs formulations were incubated with the cells for 24 hours. We used 
2 controls: one of 100% of viability (cells without the lipid-CWSPs formulation) and another of 
100% of toxicity (cells with toxic concentration of dimethyl sulfoxide (DMSO)). After the 
incubation time, 50 μl of MTT were added and incubated for 2 hours at 37 ºC. Next, 500 μl 
DMSO/Ethanol (1:1 (v/v)) were added to allow crystals to dissolve. Absorbance was read at 
570 nm. The blank used was DMSO/Ethanol (1:1 (v/v)). 
Chapter 4 - Results and Discussion 
23 
 
Chapter 4 – Results and Discussion 
 
4.1 Analysis of the CWSPs extracted 
 
Candida species have become the fourth most common cause of bloodstream infections 
and despite the improvement in chemotherapy the mortality rate for invasive candidiasis has 
remained stable in these two past decades (Pfaller et al., 2010). These observations underline 
the need for the development of novel approaches to tackle fungal infections, such as vaccines.  
C. albicans cell wall surface proteins (CWSPs) are important targets for the host immune 
system (Castillo et al., 2008). Thus, the main objective of this work was to prepare lipid-protein 
vesicles by the incorporation of CWSPs into two lipid systems and compare both their physical 
characteristics and in vitro cytotoxicity. The selected formulations could be used in a future 
immunomudulatory strategy against systemic candidiasis. 
The first task of this work entailed the incorporation of CWSPs into two types of delivery 
systems, a phospholipid system based on phosphatidylethanolamine (PE) and a synthetic 
system based on DODAB:MO. In order to obtain the CWSPs, a method based on the reducing 
agent DTT was used to extract proteins that are non-covalently attached to C. albicans cell wall 
surface. To confirm that this method did not disrupt the cell membrane, because it was 
important to avoid cytoplasmic proteins, membrane integrity of C. albicans cells was evaluated, 
through flow cytometry, before and after the treatment with DTT (Figure 9).  
 
 
Figure 9 – Flow Cytometry results of yeast membrane integrity. A. Autofluorescence of C. albicans cells. B. 
Positive control with non-viable cells. C. Membrane integrity before treatment with DTT. D. Membrane integrity 
after treatment with DTT.  
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For autofluorescence determination a C. albicans cell suspension with no staining was 
analyzed and is represented in Figure 9 A. As positive control a C. albicans cell suspension was 
boiled and the majority of the cells are green stained, as shown in Figure 9 B. As it is possible 
to observe in Figure 9 C and D, there is no fluorescence either before or after yeast cells 
treatment with DTT. These results demonstrate that the majority of the cells were not altered 
with respect to their selective permeability. So, it was possible to confirm that the method of 
CWSPs extraction does not compromise the cell membrane and therefore, mainly proteins of 
the surface of the cell wall are extracted. 
After the extraction procedure it was important to know the electrophoretic pattern of the 
extracted proteins. Therefore, CWSPs were prepared in denaturing conditions, separated 
through SDS-PAGE and silver stained. The CWSPs pattern obtained revealed one major band 
with a molecular weight of about 37kDa and other few less intense bands, as demonstrated in 
Figure 10. 
 
 
Figure 10- Electrophoretic pattern of the CWSPs extracted from C. albicans strain SC5314. Proteins were 
separated on a 12% SDS-PAGE gel and silver stained. The positions of the molecular mass standards (kDa) are 
indicated on the left. 
 
The reduced number bands can be explained by two reasons. First, the extraction 
method, since DTT allows the extraction of proteins that are poorly attached to the surface of 
the cell wall of C. albicans. It is known that the majority of cell wall proteins are GPI anchor or 
covalently attached to the glucans’ cell wall (Castillo et al., 2008). On the other hand, the 
proteins from the yeast cell wall are highly glycosylated, which can unable proteins to pass 
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through the gel, due to its high molecular weight (Chaffin, 2008). Three distinct putative 
phosphatases described as being DTT-extractable and belonging to the PHO family (Pho112p,  
Ph113p and Pho100) presented molecular weights between 51.3kDa and 35KDa 
(www.candidagenome.org). So, the three most intense bands presented in gel could 
correspond to these proteins. 
Although the number of bands is low the observed proteins are more than sufficient to 
be used as antigens and will be used for incorporation into the lipid vesicles purposed in this 
study. 
 
4.2 Lipid Vesicles Preparation and Characterization 
 
Once the extraction of the CWSPs was completed it was important to incorporate them 
into the lipid vesicles. For that, several formulations with PE were prepared according to two 
methods: lipid film hydration (HFL) and freeze thaw sonicate (FTS). The first requires 
evaporation of the PE-CWSPs mixture in a thin film and further hydration with a buffer. The last 
is simpler and is based on several cycles of freezing, thawing and sonication which enable the 
incorporation of CWSPs in the lipid vesicles.  
The CWSPs concentration used in this study was 50 μg/ml. It is important to mention 
that these lipid vesicles will be used in an immunomudulatory strategy, in which mice will be 
immunized with a CWSPs concentration of around 10 μg/dose. For that reason and accepting 
that the incorporation efficiency of CWSPs into the lipid vesicles will be lower than 100%, we 
started with a higher concentration of protein (50 μg/ml).  
Table 2 summarizes the variables used in the preparation of the different lipid-CWSPs 
formulations, namely: lipid concentration, preparation method (HFL or FTS), buffer (KPi, or 
PBS) used for lipid hydration, Lipid:MO ratio. 
 
Table 2: Variables used in the lipid vesicles prepared.  
 
Lipid 
Concentration 
(mM) 
Preparation 
Method 
 
Buffer 
Lipid:Mo 
Ratio 
PE 
0.3 HFL 
KPi  - 
0.3 FTS 
0.6 HFL 
0.6 FTS 
1.3 HFL 
1.3 FTS 
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PE:MO 
0.3 HFL 
KPi 1:2 0.6 HFL 
1.3 HFL 
DODAB:MO 
0.1 HFL 
PBS 1:2 0.3 HFL 
0.6 HFL 
- Not applicable 
 
The first lipid-CWSPs vesicles prepared in this study were the PE-CWSPs using the two 
methods of preparation, the FTS and the HFL method. After the PE-CWSPs preparation two 
important physicochemical characteristics were evaluated: liposome size and polydispersity 
index (PDI) (Figure 11). 
 
 
Figure 11- Physicochemical characteristics of PE-CWSPs lipid vesicles using two preparation methods: HFL and 
FTS. A. Size average of the lipid vesicles and B. Polydispersity Index (PDI) of the lipid vesicles.  
 
The PE-CWSPs prepared through HFL presented size averages between 268.9 nm and 
492.4 nm whether prepared through FTS presented sizes ranging from 93.5 nm to 339.7 nm.  
Analyzing the variance of the PE-CWSPs prepared through HFL we observed that an 
increase in the PE concentration of the vesicles prepared through HFL was associated with an 
increase in the PE-CWSPs vesicles size average. The values of polydispersity index (PDI) in 
these vesicles were around 0.6.  
Regarding PE-CWSPs vesicles prepared through FTS an increase in the PE concentration 
was also associated with an increase in the size. The PDI values vary from 0.48 to 0.94, 
however the deviation values were much higher. The formulation with a PE concentration of 
1.3mM was prepared but, it was not possible to dissolve the lipid. Thus, no physicochemical 
characteristics could be determined. Since the preparation method that allowed the 
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characterization of the three formulations was HFL, this method was further used in the lipid 
vesicles preparation. 
Monolein (MO) is an amphiphilic neutral lipid that has been used as a novel helper lipid 
with success in transfection experiments. It was demonstrated that the inclusion of helper 
lipids in the liposomal formulation facilitates the fusion of the complexes with the cell 
membrane (Oliveira et al., 2010; Silva et al., 2011). Thus, in this study MO was used to 
prepare the PE:MO-CWSPs formulations and these lipid formulation were compared with 
DODAB:MO-CWSPs previously tested by our group. DODAB:MO-CWSPs formulations have been 
prepared in our laboratory with different ratios, 2:1, 1:1 and 1:2, and it was observed that an 
increase in MO concentration resulted in DODAB:MO-CWSPs vesicles with lower average sizes 
and PDIs (data not shown). Thus, in this study the ratio that was selected was 1:2. Both 
PE:MO-CWSPs and DODAB:MO-CWSPs were prepared through HFL and the average sizes and 
PDI values are depicted on Figure 12 A and 12 B, respectively. 
 
 
Figure 12- Physicochemical characteristics of PE:MO-CWSPs and DODAB:MO-CWSPs lipid vesicles using HFL 
method. A. Size average of the lipid vesicles and B. Polydispersity Index (PDI) of the lipid vesicles.  
 
Regarding the PE:MO-CWSPs vesicles size, it ranged between 247.5 nm and 625.3 nm 
whether in DODAB:MO-CWSPs it varied between 250.8 nm and 732.5 nm. DODAB:MO-CWSPs 
presented lower PDI values (around 0.3 to 0.5) than the others lipid vesicles (around 0.6). 
Curiously, in PE:MO-CWSPs vesicles an increase in the lipid concentration was 
associated with a decrease in the lipid vesicles size average contrary to the trend observed in 
DODAB:MO-CWSPs and PE-CWSPs vesicles.  
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In conclusion these results indicate that, in general, increasing the lipid content 
increases the size average of the lipid vesicles, except for PE:MO-CWSPs formulations. In order 
to understand these differences we reviewed the ultrastructures described for these lipid 
formulations. 
PE vesicles constituted of phosphatidylethanolamine alone, an anionic lipid, form 
unilamellar closed vesicles resembling cell membranes (Shailesh et al., 2009). In order to 
confirm the formation of closed vesicles the incorporation of a fluorescent probe in the PE-
CWSP vesicles was performed. The probe used was FM1-43 that is described to be relatively 
non-fluorescent in aqueous solution but becomes highly fluorescent in lipid cell membrane 
environment (Nunez et al., 2000). Thus, FM1-43 was incubated with the PE-CWSPs vesicles 
suspension and analyzed through flow cytometry.  Results showed that the lipid vesicles 
emitted high fluorescence, indicating the incorporation of the probe (Figure 13). As this probe 
incorporates into the membrane it is possible to suggest a membranar closed structure for our 
vesicles. 
 
 
Figure 13 – Flow cytometry analysis of FM1-43 incorporated into PE vesicles. A. Autofluorescence of the PE 
vesicles. B. Fluorescence of PE vesicles after the incubation with FM1-43. 
 
Thus, it is comprehensive that the increase in lipid concentration increases the size of 
the lipid vesicles.  
Regarding the inclusion of MO in the PE-CWSPs vesicles it was not possible to evaluate 
them with the probe FM1-43. Considering the effect of MO on DODAB vesicles structures it has 
been shown that the inclusion of MO decreases the size of the lipid vesicles (Oliveira et al., 
2012). However, this pattern was not observed in this study from the PE-CWSPs to PE:MO-
CWSPs vesicles, nevertheless it is important to refer that the deviation values are very high to 
confirm a trend. It is also possible that the incorporation of CWSPs could alter the structures of 
the lipid vesicles reverting the pattern observed with the DODAB:MO vesicles due to the 
interactions with PE, an anionic lipid, in contrast with the interactions with DODAB, a cationic 
lipid. 
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Regarding DODAB:MO-CWSPs vesicles, the increase in the lipid vesicles size related to 
an increase in the lipid concentration has already been shown for a wider range of DODAB:MO 
concentrations by our group (data not shown).  
It is important to mention that the structural organization of these vesicles depends on 
the lipid concentration, the method of preparation, the solvent composition, the temperature 
and the presence of other substances (Neves Silva et al., 2008). So, the real structures of PE-
CWSPs and PE:MO-CWSPs need to be confirmed through a microscopic technique such as 
cryo-TEM. 
It is also clear from the results of this study that PE-CWSPs vesicles present, in general, 
higher PDI values than DODAB:MO-CWSPs vesicles. This indicates that PE-CWSPs vesicles are 
more heterogeneous, once values close to 0 indicate a homogenous dispersion while those 
greater than 0.3 indicate heterogeneity (Varshosaz et al., 2009). 
These evaluation of the physicochemical characteristics together with the CWSPs 
incorporation efficiency are critical for the choice of which lipid vesicles will continue for further 
tests. Thus, next we calculated the incorporation efficiency of CWSPs into the prepared 
vesicles. 
 
4.3 Determination of Incorporation Efficiency 
 
More than the structural characterization, the ability of these vesicular systems to 
incorporate CWSPs is crucial (Mugabe et al., 2006). This ability can be referred as 
incorporation efficiency (IE). 
In this study, after the preparation of the lipid vesicles formulations ultracentrifugation 
was performed in order to separate the supernatant with the non-incorporated CWSPs from the 
pellet with the lipid vesicles and the incorporated CWSPs. 
Thus, after the ultracentrifugation, the IE values were calculated by quantifying CWSPs 
through a protein assay quantification. 
Firstly, the Bradford method was used to directly measure the non-encapsulated protein. 
As it is possible to observe in Figure 14 the protein concentration measured in a lipid-CWSPs 
formulation before centrifugation was higher than the total CWSPs used in the assay. Besides, 
the protein concentration in the pellet that has the majority of the lipid vesicles is also higher 
than in the initial CWSPs.  
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Figure 14 – Protein quantification using the Bradford Method. P refers to the pellet after centrifugation, whereas 
S refers to the supernatant. Lipid-CWSP BC refers to the Lipid-CWSP aliquot before centrifugation.  
 
These results indicate that lipids interfere with the protein quantification through 
Bradford assay. Kruger (Kruger, 1994) had already stated the existence of several interferents 
in the Bradford assay, such as lipids and detergents, and to overcome this problem several 
methods were tested.  
Zhu and coworkers (Zhu et al., 2011) developed a vaccine anti-malaria (AMA1-
C1/ISA720) using Montanide® ISA 720, a squalene-based water-in-oil adjuvant. They were 
able to quantify the total protein concentration in this vaccine after the removal of the oil phase 
through an n-butanol treatment of the formulation. Based on this study, we used the same 
protocol to try to remove the lipid interference from the samples. However, during the 
separation protocol the CWSPs instead of being solubilized in the aqueous phase precipitated 
between the aqueous and the organic phase. This problem turned this method inappropriate 
for these CWSPs quantification.  
Thus, another separation protocol was assessed. In this second approach lipid vesicles 
were subjected to a delipidation method based on methanol and chloroform (Wessel and 
Flugge, 1984) and then CWSPs were quantified through the Bradford Method (Figure 15).  
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Figure 15 – Protein quantification through the Bradford Assay after samples treatment with methanol and 
chloroform (Wessel and Flugge, 1984). P refers to the pellet after centrifugation, whereas S refers to the 
supernatant. 
 
Considering the amount of protein before and after methanol/chloroform treatment we 
can observe that before the treatment we have 50 μg/ml and after the treatment we recovered 
only 27.66 μg/ml. We also observed that from the 27.66 μg/ml of CWSPs 17.39 μg/ml were 
in the supernatant while 6.51 μg/ml were in the pellet, making up a total of 23.85 μg/ml. 
However, the yield of protein recovery with this method was just 45.47%. Since the 
incorporation efficiency of CWSPs in the lipid vesicles should be less than 100% and if we 
consider calculating the IE measuring the protein in the supernatant and in the pellet after 
ultracentrifugation with this procedure we would lose around 45% of the protein and 
consequently, could not measure the protein concentration accurately. As the yield of this 
procedure was low, another protocol was applied.  
Xu and co-workers (Xu et al., 2012) encapsulated the protein superoxide dismutase in 
liposomes and treated them with Triton X-100 before protein quantification. Thus, we tested 
the lipid-CWSPs vesicles following the same protocol. After the samples treatment with Triton X-
100 we try to quantify the proteins with the Bradford assay. However, the interference of the 
Triton X-100 was clear since all the samples (CWSPs, Lipid-CWSPs supernatant, Lipid-CWSPs 
pellet) and PBS turned blue after the addition of the Bradford Reagent. As Triton X-100 
interfered dramatically with the Bradford Reagent we tried another quantification method, the 
BCA method. As it is possible to observe in Figure 16 when comparing the initial CWSPs (50 
μg/ml) with the CWSPs after the treatment with Triton X-100 the concentration of the protein 
was much higher, 111 μg/ml. It was also possible to see the same interference in the pellet 
Chapter 4 - Results and Discussion 
32 
 
and in the supernatant of the lipid vesicles after ultracentrifugation. Regarding the lipid alone 
there is no measurement. 
 
 
Figure 16 - Protein concentration measurement with BCA method, after samples treatment with Triton-X. P 
refers to the pellet after centrifugation, whereas S refers to the supernatant. 
 
As the treatment with Triton–X seems to interfere with the protein in both the Bradford 
and the BCA measurements another method to remove lipid interference was used. For that, 
we followed a standard protocol of protein precipitation with TCA, according to Tech Tip #8 of 
Thermo Scientific. As it is possible to observe in Figure 17 A the concentration of CWSPs 
before (initial CWSPs) and after the treatment with TCA method is approximately the same. The 
sum of the protein concentration in the pellet and in the supernatant makes up 64.19 μg/ml 
and is higher than in the CWSPs after the TCA precipitation (45 μg/ml). So, this prompted us 
to measure the concentration of protein in a Lipid-CWSPs formulation before centrifugation and 
in fact the value (70.15 μg/ml) was similar to the obtained with the sum of the values obtained 
for the supernatant and the pellet. The lipid alone showed no measure at 562 nm.  
 
 
Figure 17– TCA precipitation and BCA quantification of CWSPs. A. Protein concentration measurements. B. 
Incorporation efficiency determined after protein concentration measurements.  
Chapter 4 - Results and Discussion 
33 
 
We considered that with this protocol it was possible to successfully separate proteins 
from the lipid interferents, and with a residual loss of protein. This protocol was further used 
for the measurements of incorporated and non-incorporated proteins and the incorporation 
efficiency of the liposomes was calculated according to the following formula: 
 
 E(   100 (
Protein  oncentration in Supernatant
Protein  oncentration in Supernatant Protein  oncentration in Pellet
 100) 
 
Results from the IE calculations of the lipid vesicles prepared in this study through the 
HFL are depicted on Figure 17 B. Regarding PE-CWSPs vesicles, the formulation with a lipid 
concentration of 0.6 mM presented the highest incorporation efficiency, 42.3%. The three 
PE:MO-CWSPs vesicles presented similar IE values (around 25%) with the formulation of 
PE:MO(0.3 mM)-CWSPs presenting a slight higher value (28.6%). Concerning DODAB:MO-
CWSPs vesicles, the formulation with a lipid concentration of 0.3 mM presented the highest IE 
value of 50.6% and the DODAB:MO (0.1 mM)-CWSPs presented an IE value of 44.4%. The 
formulation DODAB:MO-CWSPs with the lipid concentration of 0.6 mM formed aggregates and 
thus, it was not possible to determine the IE value. 
If we analyze trends, we observe that in PE-CWSPs vesicles increasing the lipid 
concentration from 0.3mM to 0.6mM an increase in the IE is observed, but in the formulation 
with 1.3mM the IE value decreased to 16.46%. In PE:MO-CWSPs an increase in lipid 
concentration seems to be related to a slight decrease in IE values from 28.6% to 21.8%, but 
the trend is not clear. In DODAB:MO-CWSPs an increase in lipid concentration is related to an 
increase in the IE values.  
When comparing all the formulations, DODAB:MO-CWSPs vesicles presented the highest 
incorporation efficiencies. If we consider that the DODAB:MO-CWSPs vesicles presents similar 
structures as the described with DODAB:MO-DNA it is believed that the lamellarity of 
DODAB:MO vesicles, with cubic phases, promotes the entrapment of a higher number of 
molecules then the simpler structures with a phospholipid membrane. 
When relating the IE values with the lipid vesicles size in all formulations an increase in 
the lipid vesicles is related to an increase with the IE. This tendency is only reverted from PE-
CWSPs (0.6 mM) to PE-CWSPs (1.3mM) and we believed that this may be an error, and in the 
future more IE measurements will be made in order to confirm this. These results were 
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expectable because it is reasonable to infer that there are more CWSPs incorporated in larger 
vesicles. 
 
4.4 In vitro assays 
4.4.1 Cytotoxicity Assays 
 
The following purpose of the study was the incubation of the lipid vesicles with cells from 
the J774 cell line, to assess the in vitro cytotoxicity. For that, we selected the lipid vesicles with 
the best features regarding the physicochemical characteristics (size and PDI) and the 
incorporation efficiency. 
Liposomes size has a great influence on efficiency of liposomes as drug carriers, and on 
their targeting to specific cells. In this study, it is important that liposomes have a size average 
between 200 nm and 800 nm (Kelly et al., 2011), because the main propose of the vesicles 
will as antigen carriers target to antigen presenting cells (Brewer et al., 1998). In this view, all 
of the formulations respect this characteristic. The criterion used in regard to PDI was to 
choose the formulation with the lowest PDI in each group of the lipid vesicles. Regarding IE the 
criterion was to choose formulation with an IE higher than 40%. 
In this view regarding PE-CWSPs vesicles the one selected to continue for the cytotoxicity 
assays was PE (0.6 mM)-CWSP that presented lower PDI and higher IE when comparing to the 
other PE-CWSPs vesicles. In PE:MO-CWSPs formulations, all presented IE values much lower 
than 40% and also high PDI values. So, all of these formulations were excluded for further 
tests. Concerning DODAB:MO-CWSPs vesicles, the lipid vesicles selected to be tested were 
both DODAB:MO (0.1mM)-CWSPs and DODAB:MO (0.3 mM)-CWSPs because they presented 
lower PDI then DODAB:MO (0.6mM)-CWSPs and IE higher than 40%. 
In order to assess the in vitro cytotoxicity of the lipid-CWSP vesicles MTT assay was 
performed. For that, PE and DODAB:MO formulations with CWSPs were incubated with cells 
from J774 cell line for 24 hours then MTT was added and in viable cells it was converted into 
formazan. The viability results are presented in Figure 18. 
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Figure 18- Viability percentage of J774 cells when incubated for 24 hours with the following formulations: PE 
(0.6mM), PE-CWSPs (0.6mM), DODAB:MO (0.1mM and 0.3mM), DODAB:MO-CWSPs (0.1mM and 0.3mM) and 
CWSPs.  
 
Empty vesicles, i.e. without CWSPs, were also prepared in order to evaluate lipid 
cytotoxicity. 
No effect on cells viability was observed after incubation with CWSPs alone, indicating 
that the protein was not cytotoxic. No cytotoxicity was observed when cells were incubated with 
the Lipid-CWSPs, indicating that regardless the lipid used, PE or DODAB:MO none is cytotoxic 
for these cells. It was also possible to observe that the incorporation of the CWSPs in the lipid 
vesicles resulted in an increase in cell viability, either in PE-CWSPs or in DODAB:MO-CWSPs 
formulations, indicating that the lipids alone are more cytotoxic than the formulation with 
protein. PE alone is more toxic, with a cell viability percentage of 76.5%, than DODAB:MO that 
presented a cell viability percentage of 85.9 % with a lipid concentration of 0.1mM and 87.75% 
in with a lipid concentration of 0.3mM.  
According to Neves Silva and co-workers (Silva et al., 2011) the lipoplexes, in which DNA 
was incorporated into DODAB:MO vesicles, did not demonstrate cytotoxicity effects in 293T 
cells, which is in accordance with our results. 
The results obtained in this study are important since they show that neither PE-CWSP 
nor DODAB:MO–CWSP formulations are toxic for macrophages of J774 cell line. However, to 
further confirm these results another assay should be used, for example the LDH assay and 
another cell line should also be used to assess cytotoxicity.  
In conclusion after the characterization of these two systems it is important to say that 
DODAB:MO delivery system is a more homogeneous system and with higher incorporation 
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efficiency (>44%) of the CWSPs when compared to PE system. Thus, after this work we would 
select DODAB:MO-CWSPs vesicles to continue the studies towards the development of a 
vaccine against C. albicans. However, other parameters must be considered. 
Kelly and coworkers (Kelly et al., 2011) reviewed the relation between liposomes size 
and liposome charge and its uptake by cells from the mononuclear phagocytic system (MPS).  
They mention a study performed by Epstein-Barach and co-workers (Epstein-Barash et 
al., 2010) where they conclude that small negatively charged liposomes were optimum for 
internalization by cells from MPS while large and positively charged liposomes induced 
cytokines and toxicity by these cells. Regarding the liposome charge it is described that, in 
general, cationic liposomes are associated with efficient cellular delivery of drugs but, can 
cause more cytotoxicity than neutral and anionic liposomes. This drawback can be mainly  due 
to the charge mediated interactions between the cell (anionic) and the liposomes (cationic) 
causing high levels of uptake and subsequent lysis (Henriksen-Lacey et al., 2011).  
Thus, we opt to select the three formulations PE (0.6mM)-CWSPs, DODAB:MO (0.1mM)-
CWSPs and DODAB:MO (0.3mM)-CWSPs prepared through HFL method to continue the 
studies towards the development of a vaccine against C. albicans. 
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Chapter 5 – Conclusions and Perspectives 
 
Fungal pathogens represent the major eukaryotic agents of serious infection in European 
countries, in which infections due to Candida albicans and Aspergillus fumigatus are the most 
common and clinically important (Pfaller et al., 2010).  
The advancements of medicine, surgery and transplantology in the last thirty years have 
caused a dramatic increase in the number of immunocompromised individuals who are more 
susceptible to fungal infections. Cancer chemotherapy, neutropenia, organ transplantation, 
indwelling catheters and devices, autoimmune diseases, burns, antimicrobial therapy, 
abdominal surgery, radiotherapy or intensive care are among the main risk factors 
predisposing for Candida infection (Sabino et al., 2010). It has been estimated that in the 
United States the healthcare cost associated with candidemia is around $2–4 billion/year. 
These observations underline the urgent need for novel approaches to combat fungal infections 
and, a vaccine that could prevent or ameliorate these infections would be of major benefit to 
global health, and national healthcare systems. The development of lipid vesicle delivery 
systems that can target monocytes/macrophages is crucial and could potentially open up new 
treatment strategies for a range of diseases in which the cell-mediated immune response is 
important, as it is for fungal infections(Christensen et al., 2011). 
The present study was developed in order to compare two distinct lipid systems, one 
constituted by phosphatidylethanolamine and another composed by DODAB:MO regarding their 
ability to incorporate antigenic CWSPs for a future development of a safe and effective vaccine 
against C. albicans.  
With this work, it was possible to successfully extract proteins of the cell surface of C. 
albicans that are known to be highly immunogenic. The electrophoretic profile presented one 
major band at 37KDa with others less intense bands. The CWSPs were successfully 
incorporated into the lipid vesicles using two different methods: Lipid film hydration (HFL) and 
Freeze-Thaw-Sonicate (FTS). Three different types of vesicles were prepared, PE, PE:MO and 
DODAB:MO. 
After the incorporation of the CWSPs in the lipid vesicles three characteristics were 
analyzed: size, PDI and incorporation efficiency. Regarding the vesicles size different behaviors 
were observed. In PE-CWSPs and DODAB:MO-CWSPs vesicles an increase in the lipid 
concentration was related with an increase in the lipid vesicles size, from 268.9 to 492.5nm 
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and from 250.9 nm to 732.5 nm respectively. However, in PE:MO-CWSPs formulations, 
increasing the lipid concentration led to a decrease in lipid vesicles size, from 247.5 nm to 
625.3 nm. These different behaviors may be explained by the ultrastructures that these lipid 
vesicles form with the CWSPs that should be clarified by cryo-Tem tests.  
According to previous results with DODAB, it was expected that the incorporation of the 
MO into the PE vesicles lead to a decrease in the vesicles size, however in this study this trend 
was not observed. This could be probably due to the different interactions between MO with the 
anionic lipid PE and with the cationic lipid DODAB.  
In general, PE vesicles were more heterogeneous than DODAB:MO-CWSPs, presenting 
higher values of PDI.  
The incorporation efficiency (IE) was determined after the optimization of the delipidation 
method. In PE-CWSP lipid vesicles the formulation with a lipid concentration of 0.6mM had the 
highest value of IE, 42.3%, while in PE:MO-CWSP lipid vesicles the IE values were similar and 
generally low, around 25%. Regarding the DODAB:MO-CWSPs vesicles the formulation with the 
highest IE value was DODAB:MO(0.3 mM)-CWSP with 50.6%. 
It was also observed that in all formulations the IE values were correlated with the size of 
the lipid vesicles: an increase in the vesicle size was related with an increase in the IE values. 
These results were expected because it is reasonable to believe that there are more CWSPs 
incorporated in larger vesicles.  
Three formulations (PE (0.6mM)-CWSP, DODAB:MO (0.1mM)-CWSP and DODAB:MO 
(0.3mM)–CWSP) were selected for the in vitro cytotoxicity assays according to three criteria: 
size average between 200 nm and 800 nm, low PDI values and IE higher than 40%. 
Cytotoxicity tests in the J774 cell line showed that all the lipid-vesicles are non-toxic when 
incubated for 24hours. 
With the information collected in this work it is possible to conclude that the three 
formulations are suitable for the development of a vaccine against C. albicans. However, 
although with IE of around 40%, PE-CWSPs system showed high heterogeneity, PDI of 0.5. In 
order to overcome the heterogeneity of this system the lipid suspension could be subjected to 
extrusion. On the other hand, DODAB:MO delivery system was the most homogeneous system 
and the one with the highest IE values (>44%) of the Lipid-CWSPs formulations tested.  
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In order to complete this work zeta potential measurements are necessary as well as 
stability tests, two important characteristics of liposomes that were not approached during this 
work period. Regarding the in vitro tests it is important to perform several assays, including 
cytotoxicity tests with another cell line and using another method, quantification of ROS and 
NOS, ability of the lipid vesicles to enhance C. albicans phagocytosis and also evaluation of 
cellular uptake of the lipid-CWSPs vesicles.  
In summary with this work we were able to incorporate the CWSPs extracted into two 
types of lipid vesicles and evaluate several important characteristics such as size, PDI, IE and 
in vitro cytotoxicity. Three lipid-CWSPs formulations were selected, PE-CWSP (0,6mM), 
DODAB:MO-CWSP (0.1mM) and DODAB:MO-CWSP (0.3mM), according to the evaluated 
parameters, and considered suitable for the development of a vaccine against C. albicans.  
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